Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700680 | 0.95 | ALDH1A1 (0.33) | ALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL10833373 | 0.95 | ALDH1A1 (0.33) | ALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL325355 | 0.94 | ALDH1A1 (0.37) | ALDH1A1OPRM1OPRD1OPRK1LCK | |
| Hydrochloric Acid SCHEMBL11320260 | 0.92 | ALDH1A1 (0.35) | ALDH1A1OPRM1OPRD1OPRK1LCK | |
| SCHEMBL11257285 | 0.90 | LCK (0.35) | ALDH1A1OPRM1OPRD1OPRK1LCK | |
| SCHEMBL7735150 | 0.90 | OPRM1 (0.31) | ALDH1A1OPRM1OPRD1OPRK1 | |
| SCHEMBL16893342 | 0.89 | ALDH1A1 (0.33) | ALDH1A1OPRK1LCK | |
| Hydrochloric Acid SCHEMBL4154585 | 0.87 | LCK (0.32) | ALDH1A1OPRM1OPRD1OPRK1LCK | |
| SCHEMBL11449276 | 0.85 | — | — | |
| SCHEMBL20442807 | 0.84 | TSHR (0.36) | ALDH1A1LCKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3718551-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| CN-111671767-B | Proton-binding polymers for oral administration | 特里赛达公司 | 2024-03-08 | — | — | CN | claimed |
| CN-116211887-A | Composition for treating acid-base imbalance | 特里赛达公司 | 2023-06-06 | — | — | CN | claimed |
| CN-113855703-A | Proton binding polymers for oral administration | 特里赛达公司 | 2021-12-31 | — | — | CN | claimed |
| CN-107428955-B | Proton binding polymers for oral administration | 特里赛达公司 | 2021-09-21 | — | — | CN | claimed |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-07-08 | — | — | US | claimed |
| EP-3831395-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2021-06-09 | — | — | EP | claimed |
| EP-3593808-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-3718551-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2020-10-07 | — | — | EP | claimed |
| EP-3578185-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-08-05 | — | — | EP | claimed |
| EP-3229816-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | TRICIDA INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-9993500-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2018-06-12 | — | — | US | claimed |
| EP-3287133-A1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Tricida Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| US-9205107-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2015-12-08 | — | — | US | claimed |
| EP-3718551-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3812761-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250222021-A1 | METHOD OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-5373087-A | Contacting polyfunctional amine with unsaturated alkylating agent, reacting with polyfunctional compound to form polymer, contacting with halogen or hypohalous acid, crosslinking or raising pH to increase molecular weight | THE DOW CHEMICAL COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5278255-A | Crosslinking | THE DOW CHEMICAL COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0471594-A2 | Unsaturated polyaminopolymers, derivatives thereof, paper containing the polyaminopolymers processes for making all three | THE DOW CHEMICAL COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222021-A1 | METHOD OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SI | ALDH1A1 736/4885OPRM1 3891/4885OPRD1 3719/4885 |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | ALDH1A1 1451/4885OPRM1 4312/4885OPRD1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.